AIMEDBIO registers Phase I trial of BI 4060107 with Boehringer Ingelheim as collaborator
A first-in-human dose-escalation study of BI 4060107 in advanced solid tumors was registered on September 18, 2026 and is not yet recruiting.
- BI 4060107, an intravenous biological agent, is being tested in a Phase I, open-label, multicenter trial in adults with unresectable advanced or metastatic solid tumors who have exhausted other treatment options. The study is sponsored by AIMEDBIO with Boehringer Ingelheim listed as a collaborator1. The trial is not yet recruiting, with an estimated start date of October 14, 20261, and plans to enroll 90 participants across five dose-escalation cohorts1. The primary goal is to find the highest dose of BI 4060107 that patients with advanced cancer can tolerate1.
Fact check notes
- Checker's noteThe phrase 'A single trial registration was posted this period' is editorializing not supported by the source, though it is a minor framing statement rather than a factual error about the trial itself.
- Sentence removed
A single trial registration was posted this period for a solid tumor program backed in part by Boehringer Ingelheim.
unsupported: Source document does not state anything about number of registrations posted in a period; this is editorial framing not found in source.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.